Sanofi and Blackstone enter multimillion-euro partnership on bone marrow cancer drug

Blackstone is committing itself to help Sanofi’s drug, Sarclisa, reach the market in a subcutaneous formulation. A phase III study is slated to begin in a few months.
Photo: BENOIT TESSIER/REUTERS / X07241
Photo: BENOIT TESSIER/REUTERS / X07241
by CHRISTIAN BUNDGAARD, translated by daniel pedersen

Blackstone Life Sciences, which is part of the Blackstone group, has entered a collaboration with French pharmaceutical firm Sanofi, according to a joint press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading